John P. Hamill - SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc.

Issuer-level insider activity

Role
SrVP/CFO/Prin Fin & Acct Ofcr
Issuer ticker
APRE on Nasdaq
Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

Past-year transaction volume for John P. Hamill in Aprea Therapeutics, Inc.

Buys

Open market
Shares
+41,678
Avg price
$0.8613
Total value
+$35,897

Sells

Open market
Shares
Avg price
Total value

Net

Past year
Shares
+41,678
Share %
100%
Total value
+$35,897

Reported holdings for John P. Hamill in Aprea Therapeutics, Inc.

Form 4 holding SrVP/CFO/Prin Fin & Acct Ofcr

Aprea Therapeutics, Inc.

Security class
Pre-Funded Warrant
Shares / value
30,978
Estimated value
$24,999
Report date
31 Mar 2026
Price
$0.8070
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding SrVP/CFO/Prin Fin & Acct Ofcr

Aprea Therapeutics, Inc.

Security class
Stock Options (Right to Buy)
Shares / value
40,380
Estimated value
Report date
12 Mar 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Transaction history for John P. Hamill in Aprea Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .